Ligand Pharmaceuticals INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation for $39.00 per share in cash plus contingent value rights.
NASDAQ
Ligand Pharmaceuticals has increased its beneficial ownership in Pelthos Therapeutics to 49.9% through a new $9.0 million senior secured convertible note financing.
NASDAQ
SCHEDULE 13D: Ligand Pharmaceuticals Secures Major Stake in Pelthos Therapeutics Following Strategic Merger and $18M PIPE Financing
Ligand Pharmaceuticals Incorporated has become a significant beneficial owner of Pelthos Therapeutics Inc., holding 49.9% of its common stock, following the completion of a merger and a private investment in public equity (PIPE) financing.